An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
Latest Information Update: 10 Jun 2025
At a glance
- Drugs ONO 4685 (Primary)
- Indications Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Follicular lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
Most Recent Events
- 26 Jul 2024 New trial record